Publications by authors named "L Gossec"
Article Synopsis
- The study aimed to determine effective cutoff scores for the Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) based on disease activity measures in patients with PsA.
- Using data from the ReFlaP study, researchers analyzed scores to define disease states such as remission and varying impact levels, employing statistical methods to establish these cutoffs.
- Results indicated that the PsAID12 score had high diagnostic performance against established benchmarks, but further validation and expert consensus are needed to confirm the proposed cutoffs for clinical use.
Introduction: The study aimed to identify and describe disease activity trajectories over 10 years in patients with recent-onset axial spondyloarthritis (axSpA) and determine their impact on long-term outcomes.
Methods: This prospective, multicentre study (Devenir des Spondylarthropathies Indifférenciées Récentes cohort, ClinicalTrials.gov NCT) followed patients with early axSpA for 10 years.
Introduction: The specificity of ultrasonography (US) for enthesitis in psoriatic arthritis (PsA) is unclear. The objective was to analyze the specificity of US enthesitis in Mode B and using Power Doppler (PD), for the diagnosis of PsA through a systematic review with meta-analysis.
Methods: Systematic review in PubMed 2010-June 2023, of studies of adult patients with confirmed PsA with or without a control group of non-PsA patients, reporting information on US enthesitis.
Objectives: In axial spondyloarthritis (axSpA), patient-perceived quality of life/global functioning and health (GH) can be assessed using disease-specific [Assessment of SpondyloArthrit is international Society Health Index (ASAS-HI)] or generic [(3-level EuroQol 5 Dimensions (EQ-5D-3L)] scores. Our objectives were to explore the link between these scores and to define thresholds for good and poor GH.
Method: We conducted a post-hoc analysis of the cross-sectional ASAS-PerSpA study for patients fulfilling ASAS criteria for axSpA.
Article Synopsis
- The study focused on evaluating the effects of tofacitinib on fatigue in patients with ankylosing spondylitis (AS) through a phase 3 randomized controlled trial.
- Results showed that patients taking tofacitinib experienced a faster improvement in fatigue symptoms compared to those on a placebo, with significant percentages achieving noticeable relief within 16 weeks.
- The findings suggest that tofacitinib may be an effective treatment option for quickly alleviating fatigue in AS patients, providing healthcare providers with valuable information when discussing treatment plans with their patients.